Tag Archives: biologics

May, 2018

August, 2017

June, 2017

February, 2017

January, 2017

November, 2016

  • 14 November

    Eagle Pharma Enters Biosimilar Market through its Acquisition of Arsia Therapeutics

    WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals (“Eagle” or the “Company”) (NASDAQ:EGRX) today announced that it has signed a definitive agreement to acquire Arsia Therapeutics (“Arsia”), an early-stage biotechnology firm with proprietary viscosity-reducing technology and formulation know-how. The acquisition will mark Eagle’s entry into biologics, the fastest growing sector of the pharmaceuticals …

July, 2016

  • 8 July

    Amicus Acquires MiaMed Gaining Rare Disease Preclinical Program

    CRANBURY, N.J., July 06, 2016 (GLOBE NEWSWIRE) — Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, has expanded its biologics pipeline with a new preclinical program for cyclin-dependent kinase-like 5 (CDKL5) deficiency, a rare and devastating genetic neurological disease for which there is …

March, 2016

December, 2015